Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK, Safety and Tolerability of Dimolegin (DD217) in Healthy Volunteers
NCT05181241Phase 1Completed
- Sponsor
- PharmaDiall LLC
- Start
- Jan 2017
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of dimolegin in venous thromboembolism (VTE) (3 arms), sponsored by PharmaDiall LLC. Primary endpoint: Total Adverse Events (AE) at 28 Days. Started Jan 2017; status: completed.
02
Drugs
dimolegin
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT05181241.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05181241.